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or lipoprotein levels [6] [7] [8] delays the development or progression of complications in patients with type 2 diabetes mellitus. This has prompted calls for intensive multitherapy treatment. 9, 10 To date, only 4 studies of multitherapy management have been published, all of which showed major beneficial effects on long-term outcome.
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The Canadian Diabetes Association (CDA) 15 and the American Diabetes Association (ADA) 16 both publish guidelines on a regular basis and recommend that people with type 2 diabetes receive tailored, stepwise and proactive therapy including lifestyle intervention and pharmacologic treatment from a multidisciplinary team. However, neither set of guidelines has been evaluated by a prospective study.
We hypothesized that a 12-month, intensive multitherapy program provided by a multidisciplinary team would reduce fasting plasma glucose levels, hemoglobin A 1c concentrations, blood pressure and lipoprotein levels to the CDArecommended goals, that these benefits would be maintained beyond the intervention period (i.e., at least 6 months later), and that the intervention would improve patient quality of life. To assess the effects and feasibility of intensive multitherapy in the vast population of patients who are commonly seen by family practitioners and endocrinologists, we chose subjects in whom the disease was poorly controlled and who, although at very high risk of micro-and macrovascular events, 2, 4, 6 were without significant complications.
Methods
Patients with type 2 diabetes mellitus (1985 World Health Organization criteria) and receiving any therapy regimen, between 30 and 70 years of age and with hemoglobin A 1c concentrations of 8% or greater were eligible to participate in the study. We excluded patients with hypoglycemia unawareness, severe or uncontrolled cardiovascular disease (defined as a cardiovascular event within the last year), dyspnea higher than class II, 17 proteinuria greater than 300 mg/day, proliferative retinopathy (defined as growth of new blood vessels on the retina and posterior surface of the vitreous), chronic foot ul-cers or wounds, or psychiatric disease or cognitive impairment interfering with treatment compliance. We also excluded patients who were unable to perform the exercise program or detect sensation with the use of a 10-g monofilament.
Recruitment lasted 13 months. All patients who participated in educational sessions at the Diabetes Daycare Centre at our hospital were contacted by mail. Patients first received a letter explaining they would be contacted by the study coordinator to participate in a study. Other patients contacted us directly, after endocrinologists and primary care physicians in the Sherbrooke area were canvassed and newspapers advertisements were published. Prospective participants were first screened for exclusion criteria by telephone, and the design and aims of the study were explained. Thereafter, the screening visit, which included an exercise tolerance test, 17 finalized recruitment. The study was designed as a 12-month controlled trial with a 6-month post-intervention assessment. Using a blocked randomization (n = 4) stratified by hemoglobin A 1c value (< 10% and ≥ 10%), patients were assigned by an independent person using a computer program to receive intensive multitherapy or usual care. At the end of the 12-month intervention period, patients who had received intensive multitherapy resumed usual care. A final assessment was performed at 18 months.
Patients in the intensive multitherapy group each had monthly visits to the Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke, where they received individualized education regarding diet, physical exercise and information on managing diabetes, hypertension and hyperlipidemia. Between each visit, patients monitored their blood glucose levels at least twice daily and received at least 2 phone calls for information on test results, therapy adjustments and motivation.
The dietary intervention was based on the Canadian Nutrition Recommendations:
15 carbohydrates contributed 50%-55% to the total daily energy intake, total fats less than 30%, and saturated fatty acids less than 10%. Dietary compliance was assessed at baseline and at 6 and 12 months using a food record of 3 nonconsecutive days (one weekend day and 2 weekdays). The Candat software 18 was used to calculate intake of energy and nutrients.
The individualized home-based physical exercise program included use of an exercise bicycle (Weider Electronic Ergocycle, St. Jerome, Qué.) and elastic exercise bands (Hygienic Corporation, Akron, Ohio). Each session was monitored with a heart rate monitor (Polar Electro, Woodbury, NY) and included 4 phases: warm-up, cardiovascular, resistance and cool-down stretching. The frequency (3-5 times/week), duration (45-55 minutes) and intensity (50%-80% of the maximum heart rate) of the sessions were adapted to the patient's baseline exercise tolerance test 19 and progressively increased. Exercise tolerance tests were repeated at 12 months. Physical exercise was assessed using a standardized questionnaire 20 at baseline and at 6 and 12 months. The weekly exercise volume was calculated as metabolic equivalent task (MET) according to the type of activity × frequency × duration.
21
Pharmacologic therapy was introduced or increased at 3 months in patients who had not reached the treatment goals with lifestyle interventions and their current medications. Glyburide was started or increased to a maximum of 20 mg daily, metformin to a maximum of 2550 mg daily and α-glucosidase inhibitors to a maximum of 300 mg daily. If hemoglobin A 1c concentrations remained at 7% or greater after the maximum oral antihypoglycemic treatment was reached, bedtime intermediate-acting insulin was added. Then, as with those patients already taking insulin, the type of insulin (intermediate, premixed preparations, regular or lispro), number of injections (1-4) and dosages were adjusted. For hypertension, fosinopril (an angiotensin-converting enzyme inhibitor) was used as first-line therapy, and amlodipine (a calcium-channel antagonist), hydrochlorothiazide (a diuretic), atenolol (a β-blocker), irbesartan (an angiotensin-II receptor antagonist) and doxazosin (an α-blocker) were added and increased as recommended.
15 Fibrates (bezafibrate) or statins (pravastatin) or a combination of both was used as indicated.
15 ASA (80 mg daily) was given as a secondary prevention strategy. The optimal dosages and number of pills were increased according to therapeutic goals, secondary effects and patient agreement. Information about medications and compliance was obtained from detailed patient interviews at baseline and at 6, 12 and 18 months. To simplify comparisons and calculations, given that other types of antihyperglycemic, antihypertensive and lipidlowering drugs could be given to the patients in the control group, each drug dosage was calculated as a percentage of the maximum dosage according to the 1998 Compendium of Pharmaceuticals and Specialties.
Patients in the control group remained under the care of their family physician or endocrinologist or both. For ethical reasons, they were given general health and diabetes-related advice at each laboratory visit. Patients in the control group visited the the Clinical Research Centre of the Centre Hospitalier Universitaire de Sherbrooke at baseline and at 6, 12 and 18 months. Laboratory test results were given to the patients by telephone. Clinical (weight, body mass index, blood pressure) and biochemical data, as well as recommended guidelines for therapy, were mailed to their physicians.
The outcome variables were fasting plasma glucose levels, hemoglobin A 1c concentrations, blood pressure, serum lipoprotein levels and quality of life. Fasting plasma glucose levels, hemoglobin A 1c concentrations, blood pressure and serum lipoprotein levels were measured after a 12-hour, overnight fast at baseline and at 6, 12 and 18 months. Weight and height were measured, and body mass index (kg/m 2 ) was calculated. Fasting plasma glucose levels were measured using a glucose oxidaze method. Cholesterol, high-density lipoprotein cholesterol, and triglyceride levels were measured using a colorimetric process (Johnson & Johnson Ortho-Clinical Diagnostics, Rochester, NY). Low-density lip0protein cholesterol levels were calculated with the Friedewald formula. Hemoglobin A 1c concentrations were measured by high-performance liquid chromatography (Bio-Rad VARI-ANT, Hercules, Calif.). The nondiabetic reference range in our laboratory is 4.0%-6.0%. Systolic and diastolic blood pressure were calculated as the average of 3 readings taken at 2-minute intervals using the arm with the highest blood pressure, with the patient in a sitting position after 5 minutes of rest. A mercury-column sphygmomanometer was used, with cuff-size adjustment based on arm circumference.
The frequency and severity of hypoglycemic episodes or any other adverse events were recorded at each visit. Hypoglycemia was defined as any glucose measurement of 3.5 mmol/L or less, and an episode was recorded as "severe" if the assistance of another person was required.
To address quality of life, a specific questionnaire was developed and validated. Satisfaction, impact and diabetesrelated worry were scored according to a 5-point Likert scale ranging from 1 (very satisfied, no impact, no worry) to 5 (very dissatisfied, very impacted, very worried). To make the results easier to understand, scores were converted to a 100-point scale, 100 reflecting highest quality of life. A detailed description of the instrument and the validation process will be presented in a separate paper. The questionnaire was selfadministered at baseline and at 6 and 12 months.
Statistical analyses were carried out according to the intention-to-treat principle. Baseline characteristics of the 2 groups were compared using an unpaired Student's t test, χ 2 or Fisher's exact test. Outcome variables measured at baseline and at 6 and 12 months were compared using repeated-measurements analysis of covariance with the baseline values used as covariates. 22 The change in outcome variables between 12 and 18 months and between baseline and 18 months was tested with paired Student's t test or Wilcoxon test. An unpaired Student's t test or the Mann-Whitney test was used to test group differences at 18 months. Changes in proportion in the same group were assessed with the McNemar test. All p values were computed for 2-tailed tests at an α level of 0.05.
The study was approved by the ethics committee of the Centre Hospitalier Universitaire de Sherbrooke, and participants signed a written informed consent in accordance with the Helsinki declaration. Withdrew* n = 1
Excluded n = 123
Screened by telephone n = 418
Screened in person n = 195
Excluded n = 223
• refused to participate n = 129
• had CAD in the previous year n = 41
• age > 70 yr n = 9
• had type 1 diabetes n = 5
• participating in another study n = 7
• had cancer, blindness, musculoskeletal disease or Parkinson's disease n = 6 • impossible to reach n = 24
Withdrew n = 6 
Results

Baseline
Of 418 patients initially recruited, 36 patients were randomly assigned into each treatment arm (Fig. 1) . There was no significant difference between the 2 groups in age, sex, duration of diabetes, smoking or antihyperglycemic medications ( Table  1 ). The number of complications was similar in both groups. A total of 24 patients in the intervention group and 31 in the control group, or 76% of all study subjects, had participated in a 4-day diabetes education program in the 12 months before entry in the study, and 70% (n = 25 in each group) were under the care of endocrinologists in addition to their general practitioner. Glycemic indices showed poor control in all subjects (Table 1) . A total of 7 study participants (5 in the intervention group v. 2 in the control group) were normotensive, 13 (8 v. 5) were at target for systolic blood pressure, and 19 (11 v. 8) were at target for diastolic blood pressure; 23 in the intervention group and 21 in the control group were taking antihypertensive medications. No patient had a normal lipid profile, but 17 (8 in the intervention group v. 9 in the control group) were at treatment target for low-density lipoprotein cholesterol levels, 5 (1 v. 4) for total cholesterol:high-density lipoprotein cholesterol ratio and 12 (10 v. 2) for triglyceride levels; one-third (12 v. 15) were taking lipid-lowering agents. Quality-of-life scores were identical in the 2 groups (Table 2) .
At 12 months
At 12 months, a higher proportion of patients in the intervention group had achieved CDA goals for hemoglobin A 1c concentrations, diastolic blood pressure, and low-density lipoprotein cholesterol and triglyceride levels than in the control group (Table 3 ). There were no significant differences between the groups in goal attainment for fasting plasma glucose levels, systolic blood pressure or total cholesterol:highdensity lipoprotein cholesterol ratio. Results remained similar (data not shown) when we performed an analysis that included the 3 subjects who withdrew during the first 12 months (2 in the intervention group and 1 in the control group).
Although no patients achieved all of the targets, improvements were significantly greater in the intervention group compared with the control group with respect to fasting plasma glucose levels, hemoglobin A 1c concentrations, systolic blood pressure and triglyceride levels (Fig. 2, Table 4 ). Significant differences were already observed at 6 months (data not shown). There was no significant increase in weight in either study group.
Energy and fat intake (total fat, saturated fatty acids and cholesterol) decreased significantly between baseline and 12 months in the intervention group (Table 2) . In both groups, the proportion of subjects who met the recommendations for carbohydrate, total fat and saturated fatty acid intake was identical: 56%, 28% and 37%, respectively.
Exercise volume improved between baseline and 12 months in the intervention group, and the mean time during the tolerance test increased to over 6 minutes in this group. Twenty subjects had 3 or more exercise sessions per week, and those who exercised less often than 3 sessions per week were compliant with the prescribed duration and intensity of sessions (91.2% and 100%, respectively). Exercise volume did not change in the control group.
At the end of 12 months (Table 4, Table 5 ), 68% of patients in the intervention group were taking insulin compared with 40% in the control group (p < 0.05), and the dosage of insulin was increased (0.32 U/kg per day); consequently, the dosage of glyburide was decreased by 41% in those taking insulin in the intervention group. Among patients in the intervention group taking oral antihyperglycemic agents only, dosages increased (by 34% for glyburide and by 22% for metformin), but the number of pills remained stable (Table 4 ). The number of patients receiving intensive multitherapy who required 3 or more antihypertensive agents tripled over time, and dosages increased by 30%. Of 9 patients in the intervention group who were not taking antihypertensive medication at 12 months, 5 were at the target blood pressure at baseline and had remained there, and the other 4 had borderline blood pressure values (systolic blood pressure 134 [SD 3] mm Hg, diastolic blood pressure 77 [SD 9] mm Hg) and were reluctant to start treatment. Lipid-lowering medication was prescribed for 29 patients in the intervention group, and dosage increased by 50%.
Of 5 patients in the intervention group with hypolipidemia, 4 reached low-density lipoprotein cholesterol and triglyceride targets with lifestyle changes only, and one patient, who refused hypolipidemic agents, did not achieve the targets.
No change was observed in the number or dosages of antihyperglycemic, antihypertensive or antihyperlipidemic prescriptions in the control group.
Overall, 42% of participants experienced at least one minor hypoglycemic episode per month. The mean number of episodes per month was similar in both groups (1.7 in the intervention group v. 1.9 in the control group). In the intervention group, 3 severe hypoglycemic episodes (one concomitant with acute alcohol intoxication) were reported. Two nonlethal cardiac events were reported in each group.
Quality-of-life scores improved significantly in both groups (Table 2 ). However, this improvement was significantly greater 
At 18 months
At 18 months, or 6 months after the intervention stopped, hemoglobin A 1C concentrations, systolic blood pressure and body weight had increased significantly in the intervention group. Exercise volume had decreased in the intervention group (-10.62 [SD 13.32] METs, p < 0.001) and in the control group (-4.19 [SD 10.24] METs, p = 0.015), with no difference between the groups when decreases in exercise were expressed as percentages of 12-month values. In the intervention group, time devoted to exercise had negative correlations with weight (r = 0.363, p = 0.041) and with systolic blood pressure (r = 0.430, p = 0.016). However, all outcome vari- (10) 3 (10) 6 (17) 6 (17) 6 (21) Both statin and fibrate
Total no. of pills/patient, mean (SD) 6.3 (3.6) 6.8 (3.4) 6.5 (3.4) 6.0 (3.0) 6.5 (3.2) 6.4 (3.6)
Note: SD = standard deviation, BMI = body mass index, BP = blood pressure, FPG = fasting plasma glucose, HbA 1c = hemoglobin A 1C , LDL-C = low-density lipoprotein cholesterol, C:HDL-C = total cholesterol:high-density lipoprotein cholesterol, OHA = oral antihyperglycemic agents, ACE = angiotensin-converting enzyme. *In the intervention group, 5 patients were and remained normotensive, and 4 patients achieved CDA lipid profile goals with lifestyle changes only. †Unless stated otherwise. Between-group comparisons of outcome variables were conducted using repeated-measurement analysis of covariance with baseline values used as covariates. Statistical differences are indicated as: ‡p < 0.05 within group. §p < 0.005 within group. ¶p < 0.05 change over time (baseline and 6 and 12 months) between groups. **p < 0.05 comparison between groups at one particular time. † †Logarithmic transformation was applied to triglyceride values.
ables remained significantly improved when compared with baseline (p < 0.03), with the exception of systolic blood pressure (p = 0.085). Medication at 18 months was maintained from that at 12 months except for the dosage of statins in the intervention group, which had increased by 12%, and sulfonylureas in the control group, which had increased by 25%.
Interpretation
Using intensive and demanding therapy for type 2 diabetes over a 12-month period is feasible, and in our study it resulted in the attainment of most of the CDA-recommended goals. A higher proportion of intervention patients than control patients achieved goals for control of hemoglobin A 1C concentrations, diastolic blood pressure, and low-density lip0pro-tein cholesterol and triglyceride levels. Intensive therapy is acceptable for patients with poorly controlled type 2 diabetes: no patient in the intervention group withdrew because of the therapy, and the quality-of-life scores were significantly improved at 12 months in that group compared with those of patients receiving usual care. However, 6 months after the intervention ended, there were no statistically significant differences in goal attainment between the study groups other than for low-density lip0protein cholesterol levels.
Our study has some limitations. For ethical reasons, patients in the control group had protocol-driven laboratory tests, and they and their physicians received information about diabetes and its management as well as the results of these tests. Thus, control group patients may have received more aggressive treatment and attention than they normally would have. Similarly, patients receiving the intensive multitherapy may have been susceptible to the Hawthorne effect (people who know that performance is being measured perform with more care than they would normally). This may also have played a role in the improvements observed in the intervention group. ciation. In day-to-day clinical practice, achieving the recommended goals may be even more difficult. Several reasons may explain these relatively disappointing results. First, in this study, the next target to reach was discussed at each visit, along with acceptance of a new medication and dosage by patients. This approach may explain why some medications were not prescribed and dosages not increased. Second, as well as patients' resistance to intensifying treatment, it is well-known that many physicians have concerns about treatment that is too aggressive. The fear of hypoglycemia for this patient population, the belief that even low or average levels of metabolic control can exert a positive effect and the idea that patients are unable to achieve recommended goals 25, 26 are strong components of practitioner behaviour. Although it is paradoxical in this experimental setting, we think that this behaviour, as well as the desire to retain patients in the trial, was present in the participating practitioners. However, the therapy given to the patients in our intensive multitherapy group was aggressive when compared with that described in a recent Canadian survey:
27 among those with high blood pressure or dyslipidemia, 76% (v. 20% in the survey) were taking statins (plus 10% who were taking fibrates) and 89% (v. 41%) were prescribed angiotensin-converting enzyme inhibitors. It is important to point out that the intervention group and control group patients were taking the same number of pills; patients in the intervention group may have experienced better outcomes because dosages were more appropriate in this group.
Hypoglycemia and weight gain are major concerns in intensive treatment. In this study, the number of hypoglycemic episodes in the intervention group was comparable to those seen in studies in which comparable fasting plasma glucose levels and hemoglobin A 1c concentrations were achieved.
1,11
However, as in the Steno-2 study, 11 we did not find a difference in the number of episodes between the 2 groups. More hypoglycemic episodes would have been recorded if lower hemoglobin A 1c concentrations had been reached. 25 Body weight was stable over the 12-month intervention period, as was also observed in 2 earlier studies, 1,11 even though many patients started or increased insulin therapy, which is usually associated with weight increase.
28
At 6 months post-intervention, body weight, hemoglobin A 1c concentrations and systolic blood pressure had increased significantly. This deterioration contrasts with the sustained quality-of-life scores achieved during the demanding multitherapy program. Thus it can be concluded that multitherapy is not detrimental to quality of life. The success of permanent lifestyle changes is dependent on patients' degree of motivation, psychosocial condition, risk profile and compliance: patient nonadherence to the lifestyle regimen is the most common barrier to care. 29, 30 Further studies are required to determine the best process for inducing long-lasting change in behaviour in type 2 diabetic patients. The Diabetes Control and Complications Trial, which studied intensive management of type 1 diabetes, also reported post-intervention worsening, but this occurred 4 years after the intervention. 31 The rapid deterioration seen in our study seems to be related to a decrease in physical activity (-50%) and probably in diet compliance, as suggested by the statistically significant increase in weight at 18 months and the negative correlations of exercise with weight and with systolic blood pressure. These results underline the importance of close follow-up organized around a multidisciplinary team that provides comprehensive and shared care. 30, 32, 33 We may conclude that patients adhered to the program as long as they were being "coached."
Our intention was not to evaluate the contribution of each component of the intensive multitherapy management separately. Many other trials have focused on one or 2 interventions. [34] [35] [36] [37] We targeted lifestyle intervention through education and intense team-based follow-up, as is recommended in national association guidelines. 15, 16 In the absence of precise recommendations, we arbitrarily chose monthly follow-up, but the intensity and frequency of the monitoring should be evaluated in future studies.
Although intensive multitherapy is feasible and effective if maintained for 12 months, the benefits vanish rapidly when the patients resume usual care. The CDA treatment goals are very difficult to reach for patients with poorly controlled type 2 diabetes.
